Connections between TET proteins and aberrant DNA modification in cancer

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology

Background:

• Aberrant DNA methylation and disrupted methylation-demethylation cycles are hallmarks of cancer, often involving tumor suppressor gene silencing.
• Ten-eleven translocation (TET) proteins are key enzymes in active DNA demethylation, catalyzing the oxidation of 5-methylcytosine (5mC) to downstream oxidized forms.
• Dysregulation of TET proteins and their product 5-hydroxymethylcytosine (5hmC) is implicated in cancer development and progression.

Purpose of the Study:

• To review the pathophysiological role of TET proteins and 5hmC in cancer.
• To examine TET protein mutations, expression anomalies, and regulatory mechanisms in hematological malignancies and solid tumors.
• To discuss the prognostic significance of TET mutations and 5hmC levels, and the therapeutic potential of targeting TET proteins and DNA methylation.

Main Methods:

• Literature review focusing on TET proteins, DNA methylation, and cancer.
• Analysis of existing data on TET mutations and expression in various cancer types.
• Discussion of metabolic enzyme interactions (OGT, IDH) and therapeutic strategies.

Main Results:

• TET proteins are crucial for active DNA demethylation, and their dysfunction is linked to cancer.
• Loss-of-function mutations and abnormal expression of TET proteins are observed in hematological and solid tumors.
• 5hmC levels may serve as a prognostic biomarker in cancer patients.
• Crosstalk exists between TET proteins and metabolic enzymes like OGT and IDH.

Conclusions:

• TET proteins and 5hmC play critical roles in cancer pathogenesis.
• Assessing TET mutations and 5hmC levels holds prognostic value.
• Targeting TET proteins and aberrant DNA methylation presents therapeutic opportunities for cancer treatment.